Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Yee

Showing results (161-170 of 188) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.
Research Square|February 23, 2026
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trialAmrita Basu, Saumya Umashankar, Michelle Melisko, et al.
Breast Cancer Research : BCR|September 13, 2017
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumorsImke H Bartelink, Brendan Prideaux, Gregor Krings, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Annals of Surgical Oncology|August 23, 2025
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Annals of Surgical Oncology|August 29, 2025
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Annals of Surgical Oncology|July 24, 2025
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Pageof 19

Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline UpdateBeverly Moy, R Bryan Rumble, Steven E Come, et al.
Research Square|February 23, 2026
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trialAmrita Basu, Saumya Umashankar, Michelle Melisko, et al.
Breast Cancer Research : BCR|September 13, 2017
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumorsImke H Bartelink, Brendan Prideaux, Gregor Krings, et al.
Cell Reports. Medicine|December 12, 2023
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 TrialRosa I Gallagher, Julia Wulfkuhle, Denise M Wolf, et al.
JCO Precision Oncology|June 17, 2025
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 TrialDenise M Wolf, Christina Yau, Michael Campbell, et al.
Annals of Surgical Oncology|August 23, 2025
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Annals of Surgical Oncology|August 29, 2025
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical TrialJulie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Cancer Cell|May 5, 2023
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapyMark Jesus M Magbanua, Lamorna Brown Swigart, Ziad Ahmed, et al.
Annals of Surgical Oncology|July 24, 2025
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical TrialRita A Mukhtar, Katrina Dimitroff, Christina Yau, et al.
Cancer Cell|May 27, 2022
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapiesDenise M Wolf, Christina Yau, Julia Wulfkuhle, et al.
Pageof 19